223 related articles for article (PubMed ID: 35596192)
21. Genomic Profiling of Circulating Tumor DNA from Patients with Extensive-Stage Small Cell Lung Cancer Identifies Potentially Actionable Alterations.
Yang J; Wang X; Lu J; Chen H; Zhao X; Gao C; Bai Y; Zhang Q; Fu X; Zhang X
J Cancer; 2021; 12(17):5099-5105. PubMed ID: 34335926
[TBL] [Abstract][Full Text] [Related]
22. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer.
Giaccone G; He Y
Semin Cancer Biol; 2023 Sep; 94():1-10. PubMed ID: 37244438
[TBL] [Abstract][Full Text] [Related]
23. Genetic alteration and PD-L1 expression profiles of Chinese patients with lung squamous cell carcinoma.
Chen Y; Kong W; Yu Z; Zhao Z
Pathol Res Pract; 2022 Mar; 231():153761. PubMed ID: 35151031
[TBL] [Abstract][Full Text] [Related]
24. DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC.
Park S; Lee H; Lee B; Lee SH; Sun JM; Park WY; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Sep; 14(9):1640-1650. PubMed ID: 31125737
[TBL] [Abstract][Full Text] [Related]
25. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
[TBL] [Abstract][Full Text] [Related]
26. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
27. Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features.
Jin W; Lei Z; Xu S; Fachen Z; Yixiang Z; Shilei Z; Tao G; Zhe S; Fengzhou L; Su WH; Chundong G
Biomed Res Int; 2021; 2021():3609028. PubMed ID: 33880365
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
[TBL] [Abstract][Full Text] [Related]
29. Repeatedly next-generation sequencing during treatment follow-up of patients with small cell lung cancer.
JiaXin Y; XiaoFeng C; PengFei C; Songchen Z; Ziling L
Medicine (Baltimore); 2023 Jun; 102(26):e34143. PubMed ID: 37390276
[TBL] [Abstract][Full Text] [Related]
30. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
31. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
32. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
[TBL] [Abstract][Full Text] [Related]
33. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
34. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
35. Small-cell lung cancers in patients who never smoked cigarettes.
Varghese AM; Zakowski MF; Yu HA; Won HH; Riely GJ; Krug LM; Kris MG; Rekhtman N; Ladanyi M; Wang L; Berger MF; Pietanza MC
J Thorac Oncol; 2014 Jun; 9(6):892-6. PubMed ID: 24828667
[TBL] [Abstract][Full Text] [Related]
36. Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature.
Wen H; Guo QH; Zhou XL; Wu XH; Li J
Front Oncol; 2021; 11():792003. PubMed ID: 35071000
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
Yu H; Xu Y; Gao W; Li M; He J; Deng X; Xing W
Front Oncol; 2022; 12():930611. PubMed ID: 36072793
[TBL] [Abstract][Full Text] [Related]
38. Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.
Bordi P; Tiseo M; Barbieri F; Bavieri M; Sartori G; Marchetti A; Buttitta F; Bortesi B; Ambrosini-Spaltro A; Gnetti L; Silini EM; Ardizzoni A; Rossi G
Lung Cancer; 2014 Dec; 86(3):324-8. PubMed ID: 25453846
[TBL] [Abstract][Full Text] [Related]
39. The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
Wei W; Shi F; Xu Y; Jiao Y; Zhang Y; Ou Q; Wu X; Yang L; Lai J
J Transl Med; 2023 Dec; 21(1):874. PubMed ID: 38041093
[TBL] [Abstract][Full Text] [Related]
40. Prognostic biomarkers correlated with immune infiltration in non-small cell lung cancer.
Xu F; Cui WQ; Liu C; Feng F; Liu R; Zhang J; Sun CG
FEBS Open Bio; 2023 Jan; 13(1):72-88. PubMed ID: 36282125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]